Literature DB >> 20543580

Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.

Thelma Thompson1, Michael Danilenko, Lyubomir Vassilev, George P Studzinski.   

Abstract

Vitamin D derivatives can induce differentiation of human acute myeloid leukemia (AML) cells. Here, we investigated if the G₁ cell cycle block associated with monocytic differentiation is modulated by the p53 status of the cells treated with 1,25D, alone or with plant antioxidants carnosic acid (C) or silibinin (S), and a p38 MAPK inhibitor SB202190 (SB), a combination (D-C/S-SB) previously shown to enhance differentiation of AML p53null cells. D-C/S-SB enhanced differentiation of OCI-AML3 (p53wt) and as expected HL60 (p53 null) cells, but not of MOLM-13 (p53wt) cells. Conversely, MOLM-13 (p53wt) cells treated with 1,25D and/or D-C/S-SB, resembled HL60 (p53 null) cells in rapid G₁ block, while OCI-AML3 (p53wt) cells showed a delayed G₁ block when treated in a similar way, indicating that there is no relationship between the p53 status and G₁ block. Western blot analysis revealed that 1,25D and D-C/S-SB increased the inhibitory phosphorylation levels MEK-1 (P-Thr286), but decreased the levels of activated ERK1/2 (Thr202/Tyr204;Thr185/Tyr187), again without any apparent relationship to the p53 status. Interestingly, the increased levels of p21(Waf1/Cip1) were insufficient to promote a G₁ block in this system, as only cell lines with increased levels of p27(Kip1) and p35Nck5a, an activator of Cdk5, showed a rapid G₁ block. Overall, our data show that the p53-p21 axis is unlikely to have a role in differentiation-associated G₁ block in AML cells with wt p53, and that this block is achieved by several, possibly co-operating but redundant pathways, that include inhibition of MEK-1 by p35Nck5a-activated Cdk5.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543580      PMCID: PMC3040853          DOI: 10.4161/cbt.10.4.12366

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  48 in total

Review 1.  Vitamin D compounds in leukemia.

Authors:  Quang T Luong; H Phillip Koeffler
Journal:  J Steroid Biochem Mol Biol       Date:  2005-08-08       Impact factor: 4.292

2.  Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.

Authors:  J F Ju; D Banerjee; H J Lenz; K D Danenberg; T C Schmittgen; C P Spears; A H Schönthal; D J Manno; D Hochhauser; J R Bertino; P V Danenberg
Journal:  Clin Cancer Res       Date:  1998-05       Impact factor: 12.531

3.  Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNK/AP-1/Egr-1 pathway.

Authors:  Qing Wang; Hagar Salman; Michael Danilenko; George P Studzinski
Journal:  J Cell Physiol       Date:  2005-09       Impact factor: 6.384

4.  Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

5.  Cyclin-dependent kinase 5 activity enhances monocytic phenotype and cell cycle traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells.

Authors:  F Chen; G P Studzinski
Journal:  Exp Cell Res       Date:  1999-06-15       Impact factor: 3.905

6.  Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.

Authors:  Kavita V Bhatt; Laurie S Spofford; Gazelle Aram; Meghan McMullen; Kevin Pumiglia; Andrew E Aplin
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

Review 7.  Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.

Authors:  Gerald Schmid; Joanna B Strosznajder; Józefa Wesierska-Gadek
Journal:  Mol Neurobiol       Date:  2006-08       Impact factor: 5.590

8.  Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway.

Authors:  M Kawada; S Yamagoe; Y Murakami; K Suzuki; S Mizuno; Y Uehara
Journal:  Oncogene       Date:  1997-08-07       Impact factor: 9.867

Review 9.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition.

Authors:  S Meloche; J Pouysségur
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 10.  Vitamin D analogs as anti-carcinogenic agents.

Authors:  E S Agoston; M A Hatcher; T W Kensler; G H Posner
Journal:  Anticancer Agents Med Chem       Date:  2006-01       Impact factor: 2.505

View more
  7 in total

1.  Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).

Authors:  Xuening Wang; Elzbieta Gocek; Victoria Novik; Jonathan S Harrison; Michael Danilenko; George P Studzinski
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

2.  Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.

Authors:  Jing Zhang; Jonathan S Harrison; George P Studzinski
Journal:  Exp Cell Res       Date:  2010-09-08       Impact factor: 3.905

Review 3.  Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells.

Authors:  X T Hu; K S Zuckerman
Journal:  Cell Prolif       Date:  2014-03-19       Impact factor: 6.831

4.  An aqueous extract of Fagonia cretica induces DNA damage, cell cycle arrest and apoptosis in breast cancer cells via FOXO3a and p53 expression.

Authors:  Matt Lam; Amtul R Carmichael; Helen R Griffiths
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

5.  Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3.

Authors:  Vanessa Wachholz; Al-Hassan M Mustafa; Yanira Zeyn; Sven J Henninger; Mandy Beyer; Melanie Dzulko; Andrea Piée-Staffa; Christina Brachetti; Patricia S Haehnel; Andreas Sellmer; Siavosh Mahboobi; Thomas Kindler; Walburgis Brenner; Teodora Nikolova; Oliver H Krämer
Journal:  Arch Toxicol       Date:  2021-10-19       Impact factor: 5.153

6.  Cell-Type-Specific Effects of Silibinin on Vitamin D-Induced Differentiation of Acute Myeloid Leukemia Cells Are Associated with Differential Modulation of RXRα Levels.

Authors:  Rina Wassermann; Victoria Novik; Michael Danilenko
Journal:  Leuk Res Treatment       Date:  2012-05-20

Review 7.  The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  J Clin Med       Date:  2015-03-25       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.